# US 2012/0083453 A1 · Treatment using neublastin polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083453 A1
- Document ID: US20120083453A1
- Status: Published application
- Kind: A1
- Application number: 13/012,408
- Filed: 2011-01-24
- Published: 2012-04-05
- Earliest claimed: 2001-03-28
- Assignees: Biogen Idec MA Inc.
- Inventors: Dinah W.Y. Sah
- Web page: https://patentgrep.com/patent/US20120083453A1

## CPC

- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 25/00: Drugs for disorders of the nervous system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.

## Claims

### Claim 1

A method for treating neuropathic pain in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide, wherein the pharmaceutical composition is administered to the subject via systemic delivery.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuropathic pain is associated with post-herpetic neuralgia, diabetic neuropathy, or sciatica.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered via intravenous delivery.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered via subcutaneous delivery.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time or increased concentration in body fluids.

### Claim 11 (depends on 10)

The method of claim 10, wherein the derivative moiety is a polyethylene glycol moiety.

### Claim 12 (depends on 10)

The method of claim 10, wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

### Claim at position 10

13-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein said neuropathic pain is associated with infection of said subject by a virus.

### Claim 28 (depends on 27)

The method of claim 27, wherein said virus is selected from the group consisting of a herpes virus, a human immunodeficiency virus (HIV), and a papilloma virus.

### Claim 29 (depends on 1)

The method of claim 1, wherein said neuropathic pain is neuropathic pain associated with administration of a therapeutic agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein said therapeutic agent is an anti-cancer agent.

### Claim 31 (depends on 30)

The method of claim 30, wherein the anti-cancer agent is selected from the group consisting of taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine.

### Claim 32 (depends on 29)

The method of claim 29, wherein said therapeutic agent is an anti-viral agent.

### Claim 33 (depends on 32)

The method of claim 32, wherein said anti-viral agent is selected from the group consisting of ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid.

### Claim 34 (depends on 1)

The method of claim 1, wherein said neuropathic pain is due to injury associated with trauma.

### Claim 35 (depends on 1)

The method of claim 1, wherein said neuropathic pain is characterized by allodynia.

### Claim 36 (depends on 1)

The method of claim 1, wherein said neuropathic pain is hyperalgesic pain.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hyperalgesic pain is thermal hyperalgesic pain.

### Claim 38 (depends on 1)

The method of claim 1, wherein said neuropathic pain is phantom pain.

### Claim at position 23

39-56. (canceled)

### Claim 57

A method for treating allodynia in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide.

### Claim 58

A method for treating hyperalgesic pain in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide.
